Related Experiment Video
Updated: Jul 19, 2026
Proplatelet Formation Dynamics of Mouse Fresh Bone Marrow Explants
Published on: May 20, 2021
Decreased platelet expression of myosin regulatory light chain polypeptide (MYL9) and other genes with platelet
L Sun1, J R Gorospe, E P Hoffman
1Sol Sherry Thrombosis Research Center and Division of Hematology, Temple University School of Medicine, Philadelphia, PA 19140, USA.
Insights
This study reveals gene expression changes in a patient with inherited platelet disorder due to a CBFA2 mutation. Platelet expression profiling identified downregulated genes crucial for platelet function and production.
Area of Science:
- Hematology
- Molecular Biology
- Genetics
Background:
- Inherited thrombocytopenia can stem from mutations in transcription factors like CBFA2 (RUNX1/AML1).
- Understanding the molecular mechanisms underlying these platelet disorders is crucial for diagnosis and potential therapies.
Purpose of the Study:
- To investigate the molecular basis of abnormal platelet function in a patient with a heterozygous CBFA2 mutation.
- To identify CBFA2-regulated genes in platelets using expression profiling.
Main Methods:
- Platelet gene expression profiling was performed on one patient and four healthy controls using Affymetrix U133 GeneChips.
- Analysis focused on identifying significantly downregulated genes in the patient's platelets.
Main Results:
- A total of 298 probe sets were downregulated at least 2-fold in the patient's platelets.
- Significant downregulation (approx. 77-fold) of MYL9 (myosin light chain) was observed, correlating with impaired MLC phosphorylation.
- Other downregulated genes involved calcium binding, ion transport, cytoskeletal proteins, signaling, and chemokines.
Conclusions:
- Platelet expression profiling is a viable approach to uncover molecular defects in inherited platelet disorders.
- Downregulated genes identified in this study are linked to the patient's specific platelet functional and production defects.
- This research provides insights into CBFA2's role in regulating platelet gene expression and function.
Abstract:
We have reported on a patient with thrombocytopenia, impaired platelet aggregation, secretion, phosphorylation of pleckstrin and myosin light chain (MLC), and GPIIb-IIIa activation, associated with a heterozygous mutation in transcription factor CBFA2 (core binding factor A2, RUNX1 or AML1). To obtain insights into the abnormal platelet mechanisms and CBFA2-regulated genes, we performed platelet expression profiling in four control subjects and the patient using the Affymetrix U133 GeneChips. In the patient, 298 probe sets were significantly downregulated at least 2-fold. MLC regulatory polypeptide (MYL9 gene) was decreased approximately 77-fold; this is an important finding because agonist-stimulated MLC phosphorylation is decreased in patient platelets. Genes downregulated > or = 5-fold include those involving calcium binding proteins (CABP5), ion transport (sodium/potassium/Ca exchanger, SLC24A3), cytoskeletal/microtubule proteins (erythrocyte membrane protein band 4.1-like 3, EPB41L3; tropomyosin 1, TPM1; tubulin, alpha 1, TUBA1), signaling proteins (RAB GTPase activating protein 1-like, RABGAP1L; beta3-endonexin, ITGB3 BP) and chemokines (platelet factor 4 variant 1, PF4V1; chemokine CXCL5, CXCL5). These and other downregulated genes are relevant to the patient's platelet defects in function and production. These studies provide the first proof of concept that platelet expression profiling can be applied to obtain insights into the molecular basis of inherited platelet defects.
